The MORE+KAP Clinical Trial, led by lead investigator Eric Garland, PhD, LCSW at the University of Utah, is the first to investigate the effects of intramuscular KAP for adult outpatients treated with buprenorphine, a first-line medication for opioid use disorder. Recent studies have shown promise for the use of ketamine in treating substance use disorders, including alcohol and cocaine use disorders.1,2 With opioid-related deaths continuing to rise across nearly all populations age 15 and older,3the MORE+KAP Clinical Trial comes at a critical time and makes an important contribution to the early evidence base for effective treatment options. The study will investigate the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy (the 'MORE+KAP Clinical Trial'). (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, today announced it will host a phase I randomized clinical trial for adults with opioid use disorder. TORONTO, ON / ACCESSWIRE / Janu/ Novamind Inc.
